Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Irritable Bowel Syndrome Pipeline Booms as 24+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

Published

on

New York, USA, Jan. 18, 2023 (GLOBE NEWSWIRE) — Irritable Bowel Syndrome Pipeline Booms as 24+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

Irritable bowel syndrome (IBS) is a group of symptoms that occur together, including repeated pain in your abdomen and changes in your bowel movements, which may be diarrhea, constipation, or both. IBS is one of the most commonly diagnosed gastrointestinal diseases.In the United States, Canada, and Isreal, IBS symptoms are 1.5 to 2 times more prevalent among women than men. Moreover, women are more likely to report abdominal pain and constipation, whereas men are more likely to report diarrhea. The prevalence of IBS also decreases with age. Increasing research and development activities by the key players in the market for the development of irritable bowel syndrome drugs are expected to drive the market growth.

DelveInsight’s ‘Irritable Bowel Syndrome Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline irritable bowel syndrome therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the irritable bowel syndrome pipeline domain. 

Key Takeaways from the Irritable Bowel Syndrome Pipeline Report

  • DelveInsight’s irritable bowel syndrome pipeline report depicts a robust space with  24+ companies and 24+ pipeline drugs for irritable bowel syndrome treatment. 
  • Key irritable bowel syndrome companies include Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, and others are evaluating novel irritable bowel syndrome drugs candidate to improve the treatment landscape.
  • Promising irritable bowel syndrome pipeline therapies in various stages of development include Olorinab, Blautix, ORP-101, BOS-589, BEKINDA, Rifamycin controlled-release, CIN 103, Crofelemer, RQ-00310941, AAT 730, and several others. 
  • In October 2022, Intrinsic Medicine and Phoenix Biotech Acquisition Corp. announced they have entered into a definitive business combination agreement. 
  • In September 2022, Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, announced the closing of a $43.5 million Series B financing. 

Request a sample and discover the recent advances in irritable bowel syndrome treatment drugs @ Irritable Bowel Syndrome Pipeline Report

The irritable bowel syndrome pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage irritable bowel syndrome products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the irritable bowel syndrome pipeline landscape.

Irritable Bowel Syndrome Overview 

According to the International Foundation for Gastrointestinal Disorders (IFFGD), Irritable bowel syndrome (IBS) is a disorder characterized by abdominal pain or discomfort and altered bowel habit (chronic or recurrent diarrhea, constipation, or both – either mixed or in alternation). Although the underlying pathogenesis is far from understood, etiological factors include increased epithelial hyperpermeability, dysbiosis, inflammation, visceral hypersensitivity, epigenetics and genetics, and altered brain–gut interactions. According to IFFGD, IBS affects people of all ages, even children. It affects between 25 and 45 million people in the United States. About 2 in 3 IBS sufferers are females, while 1 in 3 sufferers are males. IBS is diagnosed based on symptoms, and a distinction is made between the following subtypes of IBS: IBS with pain or discomfort and predominant constipation (IBS-C), IBS with diarrhea (IBS-D), mixed IBS (IBS-M), and unsubtyped IBS (IBS-U). IBS has a good prognosis, and the diagnosis is unlikely to change on follow-up. IBS diagnosis has evolved since its first discovery, and today the Rome IV diagnostic criteria (The Rome IV consensus is a robust standard for a clinical and research approach to functional gastrointestinal disorders) is used to diagnose IBS.  Irritable bowel syndrome manifests abdominal pain/discomfort and altered bowel function. Despite affecting as many adults, a lack of understanding of etiopathogenesis and evaluation strategies results in diagnostic uncertainty and, in turn, becomes an unmet need for both the patient and the physician.

Find out more about irritable bowel syndrome treatment drugs @ Drugs for Irritable Bowel Syndrome Treatment

A snapshot of the Irritable Bowel Syndrome pipeline drugs mentioned in the report:

Drug  Company Phase  MoA RoA
Olorinab Pfizer Phase II Cannabinoid receptor CB2 agonists Oral
Blautix 4D Pharma Phase II Bacteria replacements; Gastrointestinal microbiome modulators Oral
ORP-101 OrphoMed Inc. Phase II Opioid kappa receptor antagonists; Opioid mu receptor agonists Oral
BEKINDA RedHill Biopharma Phase II Serotonin 3 receptor antagonists Oral
BOS-589 Boston Pharmaceuticals Phase II Protein tyrosine kinase inhibitors Oral
Crofelemer Napo Pharmaceuticals Phase II  

Chloride channel antagonists

Oral
Rifamycin controlled-release Cosmo/Dr Falk Pharma/Salix Phase II DNA-directed RNA polymerase inhibitors Oral

Learn more about the emerging irritable bowel syndrome pipeline therapies @ Irritable Bowel Syndrome Clinical Trials

Irritable Bowel Syndrome Therapeutics Assessment

The irritable bowel syndrome pipeline report proffers an integral view of irritable bowel syndrome emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Irritable Bowel Syndrome Pipeline Report 

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Pre-clinical, Discovery, Discontinued, Inactive, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical.
  • Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
  • Therapeutics Assessment By Mechanism of Action: Cannabinoid receptor CB2 agonists, Bacteria replacements; Gastrointestinal microbiome modulators, Opioid kappa receptor antagonists; Opioid mu receptor agonists, Serotonin 3 receptor antagonists, DNA-directed RNA polymerase inhibitors
  • Key Irritable Bowel Syndrome  Companies: Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, and others. 
  • Key Irritable Bowel Syndrome  Pipeline Therapies: Olorinab, Blautix, ORP-101, BOS-589, BEKINDA, Mesalamine, Rifamycin controlled-release, CIN 103, Crofelemer, RQ-00310941, AAT 730, and others.

Dive deep into rich insights for new drugs for irritable bowel syndrome treatment, visit @ Irritable Bowel Syndrome Drugs

Table of Contents

1. Irritable Bowel Syndrome Pipeline Report Introduction
2. Irritable Bowel Syndrome  Pipeline Report Executive Summary
3. Irritable Bowel Syndrome Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Irritable Bowel Syndrome  Pipeline Therapeutics
6. Irritable Bowel Syndrome  Pipeline: Late Stage Products (Pre-registration)
7. Irritable Bowel Syndrome  Pipeline: Late Stage Products (Phase III)
8. Irritable Bowel Syndrome  Pipeline: Mid-Stage Products (Phase II)
9. Irritable Bowel Syndrome  Pipeline: Early Stage Products (Phase I)
10. Irritable Bowel Syndrome  Pipeline Therapeutics Assessment
11. Inactive Products in the Irritable Bowel Syndrome  Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Irritable Bowel Syndrome Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the irritable bowel syndrome pipeline therapeutics, reach out @ Irritable Bowel Syndrome Treatment Drugs

Related Reports

Irritable Bowel Syndrome Market

Irritable Bowel Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Irritable Bowel syndrome companies, including Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, among others.

Irritable Bowel Syndrome Epidemiology Forecast

Irritable Bowel Syndrome Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the Irritable Bowel syndrome epidemiology trends.

Ulcerative Colitis Market

Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Ulcerative Colitis companies, including Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, Celgene, among others.

Ulcerative Colitis Pipeline 

Ulcerative Colitis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Ulcerative Colitis companies, including Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, Celgene, among others.

Peptic Ulcers Pipeline

Peptic Ulcers Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Peptic Ulcers companies, including Daewoong Pharmaceutical, HK inno.N Corporation, PharmaKing, Recce Pharmaceuticals, Sequella Inc, Shandong Luoxin Pharmaceutical, RaQualia Pharma, Sihuan Pharmaceutical Holdings Group, Sinil Pharmaceutical, among others.

Peptic Ulcers Market

Peptic Ulcers Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Peptic Ulcers companies, including Daewoong Pharmaceutical, HK inno.N Corporation, PharmaKing, Recce Pharmaceuticals, Sequella Inc, Shandong Luoxin Pharmaceutical, RaQualia Pharma, Sihuan Pharmaceutical Holdings Group, Sinil Pharmaceutical,  among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Management ‘bought the AI hype’ and expect value but research shows lack of organizational readiness is primary hurdle: IFS

Published

on

management-‘bought-the-ai-hype’-and-expect-value-but-research-shows-lack-of-organizational-readiness-is-primary-hurdle:-ifs

IFS commissioned research shows value creation lags AI promise without the right planning and application
LONDON, April 23, 2024 /PRNewswire/ — New research from IFS, the global cloud enterprise software company, has found that executive and board leadership have ‘bought the AI hype’ but organizations are unable to deliver operationally on expectations. The new global study of 1,700 senior decision makers, Industrial AI: the new frontier for productivity, innovation and competition, found that the promise of AI is being held back by technology, processes and skills. Half of respondents remain optimistic that with the right AI strategy, value can be realized in the next two years, and a quarter believe in the next year.

Expectations failing to meet reality
84% of executives anticipate massive organizational benefits from AI, with the top three areas AI is expected to deliver value in being high-impact: product & service innovation, improved internal & external data availability, and cost reductions & margin gains. The hype has become so high that 82% of senior decision-makers acknowledge that there is significant pressure to adopt AI quickly. However, this same group of respondents state that they are concerned that a failure to plan, implement and communicate properly means AI projects will stall in pilot stage.
Many organizations have not prioritized elements of development, nor have the infrastructure required to reap the rewards or the skills to deliver on that promise. The study found that over a third (34%) of businesses had not moved to the cloud. While this is not essential to AI adoption, it is indicative of an unprepared enterprise unlikely to be able to scale AI across their business. According to IFS, a robust Industrial AI strategy requires a potent combination of cloud, data, processes, and skills. 80% of respondents agree that the lack of a strategic approach means they have insufficient skills in-house to successfully adopt AI. This sentiment is seen elsewhere in the research with 43% of respondents rating the quality of AI resources in their business, in terms of human skills, as passable and not where it needs to be.
Christian Pedersen, Chief Product Officer, IFS, commented: “AI is poised to become the most transformational enterprise tool ever seen, but our research reveals that there are still fundamental misunderstandings about how to harness its power within an industrial setting. It is telling that AI is expected to significantly reduce costs and raise margins, but a lack of robust strategy means most businesses are under-skilled and under-prepared to achieve these ambitions. We built IFS.ai specifically with these challenges in mind. AI value simply will not be found in a single AI capability but instead by delivering AI across all products and business processes. This supports customers’ decision cycles and provides the data and AI services required to realize value faster.”
Pedersen continued: “Achieving this at scale needs a clear-eyed strategic focus, including the high-impact use cases specific to their industry, having a cloud-based infrastructure in place which has industrial AI embedded, and investing early in developing the skills needed. Adopting this approach will turn the tide of disillusionment, and deliver the benefits that boards and the C suite are demanding.”
Outlook optimistic but planning needed
The unfortunate reality of the skills gap means that in terms of AI readiness, many businesses are falling behind. IFS found that nearly half of respondents (48%) were most likely to say that they are gathering proposals and were much less likely to have a clear strategy and perceivable results (27%). A fifth of respondents are in the research phase, with uncontrolled tests taking place and a further 5% are lacking a coordinated approach and do not have anything in motion yet. Despite initial challenges, there is still optimism with respondents most likely to feel AI could make a significant difference to their business in 1-2 years (47%), and a further quarter (24%) believe it could be within a year.
In particular, respondents are most optimistic about the impact of AI in smart production and/or service delivery on effectiveness & business and operational management (22%) in the future. One fifth see the biggest impact being on innovation with new products and services (20%), growth & business model decision-making (20%), empowering people and increasing talent retention (19%), and customer experience and customer service (19%).
Action needed on data readiness
To reap these benefits, enterprises need to leverage the most strategic asset they have – their data. The right data volume and quality is critical for the success of AI applications. Respondents recognize how important real-time data is to successful AI projects, with over 4 in 5 (86%) stating this. Yet despite this recognition, less than a quarter (23%) of respondents have completed their data foundation with it supporting both data-driven business decision making and real time response to changes, suggesting that more work needs to be done to get data AI ready. Moreover, under half (43%) of respondents have majority structured data, with some unstructured.
Pedersen commented: “The lack of maturity at the data foundation layer needs to be addressed as part of an overall AI strategy, otherwise AI simply will never be the magic bullet that can turbocharge the enterprise. Clearly enterprises need support on data management and migration. While AI is seen as a shiny new tool that will revolutionize business, like all technology, it is never that simple. The power of Industrial AI is that it can touch all facets of a business from product innovation and customer experience to productivity and ESG. Its potential is massive if executives and organizations can combine vision, strategy, technology and skills. Now is the time to step back, take stock, and build a true Industrial AI plan and turn the hype into reality.”
Methodology:
Censuswide surveyed 1,709 C-level/President/SVP/Directors who work in Manufacturing, Telecommunications, A&D, Services, Construction & Engineering or Energy & resources in organizations with $50m+ annual revenue (Aged 18+) across the UK, USA, Canada, Germany, France, UAE, Norway, Japan, Australia, Sweden, Denmark and Finland between 06.03.2024 – 27.03.2024.
IFS Press Contacts:MEA& APJ: Adam GillbeCorporate CommunicationsEmail: [email protected] Phone: +44 7775 114 856
USA: Mairi MorganCorporate CommunicationsEmail: [email protected] Phone: +44 7918 607 299
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/ifs/r/management–bought-the-ai-hype–and-expect-value-but-research-shows-lack-of-organizational-readiness,c3965172
The following files are available for download:
https://mb.cision.com/Main/855/3965172/2749130.pdf
Release
https://news.cision.com/ifs/i/ai-research-1-930×423,c3292255
AI-Research-1-930×423
 

View original content:https://www.prnewswire.co.uk/news-releases/management-bought-the-ai-hype-and-expect-value-but-research-shows-lack-of-organizational-readiness-is-primary-hurdle-ifs-302124351.html

Continue Reading

Artificial Intelligence

University medical centers in Germany choose Sectra’s radiology solution to streamline workflows and shorten lead times for patients

Published

on

university-medical-centers-in-germany-choose-sectra’s-radiology-solution-to-streamline-workflows-and-shorten-lead-times-for-patients

LINKÖPING, Sweden, April 23, 2024 /PRNewswire/ — International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed two contracts to provide the radiology module of its enterprise imaging solution with two university medical centers in Germany—Universitätsklinikum Tübingen and Universitätsmedizin Göttingen. By implementing Sectra’s radiology solution, the hospitals aim to improve and streamline radiology workflows with Sectra’s tools for enhanced reporting efficiency, in turn speeding up diagnostics.

“When choosing a vendor, we wanted one that could provide us with a stable and fast system. We also wanted one facilitating collaboration among our radiologists. That way we can streamline our radiology workflows and in turn shorten lead times for patients as well as reduce the ever increasing workload for radiologists,” says Dr. Babak Panahi, Managing Senior Physician and Head of CT and CT Intervention, Universitätsmedizin Göttingen.
Universitätsmedizin Göttingen and Universitätsklinikum Tübingen are two university medical centers located in the cities of Göttingen and Tübingen in Germany managing 300,000 and 600,000 radiology exams a year. The two separate contracts for Sectra’s radiology solution were both signed during the third quarter of Sectra’s 2023/2024 fiscal year.
“Radiologists are under a lot of pressure as they are challenged to handle more images and more complex cases with less resources. Having a solution designed to streamline radiology workflows, facilitating reading and reporting of images, is therefore paramount. I am happy and excited to support Universitätsmedizin Göttingen and Universitätsklinikum Tübingen on their journey towards efficient radiology diagnostics,” says Guido Bötticher, Managing Director, Sectra DACH.
The radiology module is part of Sectra’s enterprise imaging solution that provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Visit Sectra’s website to read more about Sectra and why it’s top-ranked in ‘Best in KLAS’.
About SectraSectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society’s most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 19 countries, and distribution partners worldwide. Sales in the 2022/2023 fiscal year totaled SEK 2,351 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra’s website.
For further information, please contact: Dr. Torbjörn Kronander, CEO and President Sectra  AB, 46 (0) 705 23 52 27Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/sectra/r/university-medical-centers-in-germany-choose-sectra-s-radiology-solution-to-streamline-workflows-and,c3965089
The following files are available for download:
https://news.cision.com/sectra/i/sectra-s-radiology-solution,c3291783
Sectra’s radiology solution
 

View original content:https://www.prnewswire.co.uk/news-releases/university-medical-centers-in-germany-choose-sectras-radiology-solution-to-streamline-workflows-and-shorten-lead-times-for-patients-302124211.html

Continue Reading

Artificial Intelligence

New CPS Protection Platform: TXOne Networks Unveils SageOne at GISec Global

Published

on

new-cps-protection-platform:-txone-networks-unveils-sageone-at-gisec-global

TAIPEI, April 23, 2024 /PRNewswire/ — TXOne Networks, a frontrunner in the realm of cyber-physical systems (CPS) security, is set to unveil its groundbreaking CPS security platform, SageOne, at the highly anticipated GISec Global from April 23rd to 25th, 2024. Attendees can find TXOne Networks showcasing SageOne at stand B99 in hall 5. This innovative platform consolidates all CPS security products onto a single, central management platform, promising streamlined operations and optimized threat detection capabilities.

SageOne, aptly named “Wise Man Number One,” serves as a comprehensive management console providing a holistic view of the CPS attack surface within operational technology (OT) environments. By enabling centralized control of TXOne’s three core product lines – Stellar for endpoint protection, Element for security inspection, and Edge for network defense – SageOne facilitates integrated OT security throughout the lifecycle of protected assets, ensuring robust threat detection and response mechanisms.
Key features of SageOne include:
CPS Attack Surface Management: Prioritizing operational security by offering clear visibility into the overall security posture of OT environments, SageOne identifies security focal points, illuminating asset information and security controls.Integrated Lifecycle Protection: Through centralized management, SageOne simplifies cybersecurity governance and fosters collaborative defense. It serves as an abstraction layer, facilitating contextualization and consolidation of data across multiple products, offering tailored, task-oriented consoles for executives, security personnel, and plant leaders.CPS Threat Detection & Response: SageOne aggregates security insights from various solutions to scout for potential risks, enabling early caution and response to both known and unknown threats.SageOne’s foundation rests upon advanced components, including Threat Intelligence, Behavior-Based AI Analytics Engines, Compliance Framework, Data Visualizer, and Ecosystem Integrator, ensuring comprehensive protection and seamless integration of different tools and technologies.
With its focus on analyzing unexpected behavior and unknown threats, SageOne enables the identification of suspicious events through cross-telemetry analysis within the OT-native XDR engine. This amalgamation of advanced technologies and user-friendly interface ensures the protection of critical infrastructures.
For rapid threat response, SageOne issues early warnings of suspicious behavior and orchestrates cross-telemetry analysis for CPS Threat Detection & Response. Integrated Lifecycle Protection ensures the security of devices and systems throughout their service life, contributing to great cost efficiency.
TXOne Networks reaffirms its commitment to CPS security and continuous advancement in OT security through SageOne. Visit TXOne Networks at the GISec Global from April 23rd to 25th, 2024, at stand B99 in hall 5.
For further updates and information, follow TXOne Networks on the blog, Twitter, and LinkedIn.
About TXOne Networks:
TXOne Networks provides OT security products ensuring reliability and security in industrial control systems and operational technology environments through the OT Zero Trust methodology. Collaborating with leading industrial manufacturers and critical infrastructure operators, TXOne Networks offers practical and business-friendly approaches to OT defense. Its network and endpoint-based products secure OT networks and mission-critical devices in real-time with high security depth.
Website: www.txone.com 
Photo – https://mma.prnewswire.com/media/2389611/SageOne_header_3.jpg

View original content:https://www.prnewswire.co.uk/news-releases/new-cps-protection-platform-txone-networks-unveils-sageone-at-gisec-global-302119386.html

Continue Reading

Trending